Wednesday 6-25-2014 Gilead Sciences (GILD) $GILD opened at 80.90 hitting the high price of 81.85 and a day low of 80.60 with a total volume of 8,665,366. GILD had a previous close of 80.81 and has been seeing an average volume of 10,002,145.
Overall Average: 64% Buy
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - 2 hrs 7 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading: (full story)
Midday Glance: Biotechnology companies
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.: (full story)
Strength Seen in Vertex Pharmaceuticals Incorporated (VRTX) as Stock Shoots 40.41% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:44AM CDT
Vertex Pharmaceuticals Incorporated (VRTX) was a big mover last session, as the company saw its shares catapult over a whopping 40% on the day. (full story)
'Fast Money' Recap: A Mixed Bag for Housing
at The Street - Wed Jun 25, 4:00AM CDT
The trading panel discussed the stock market's big drop, how low the S&P can go and why bonds aren't selling off. (full story)
Should Dividend Investors Eject AbbVie Stock?
David Williamson, The Motley Fool - Motley Fool - Tue Jun 24, 6:01PM CDT
Dividend aristocrat spin-off AbbVie (NYSE: ABBV) has one of the highest yields in health care, but does that make it one of the sector's top dividend stocks? In this video, Motley Fool Healthcare analyst David Williamson will be grading well... (full story)
Vertex Gets Out of TRAFFIC and TRANSPORTs Shares 40% Higher
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 6:01PM CDT
Sometimes good enough really is good enough. But only if you're treating the right patient population. Vertex Pharmaceuticals seems to be really good at picking them. The biotech gets a passing grade for improving lung function in its clinical... (full story)
Up 40%: Is Vertex's Surge Justified?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 24, 3:32PM CDT
Vertex has been one of the most hit-and-miss investments in the biotech industry over the past five years, but investors who have hung in through thick and thin have been rewarded. Despite a short-lived run as the globe's pre-eminent leader in... (full story)
Better Stock Today Challenge: Gilead vs. Kinder Morgan Partners
David Williamson and Joel South, The Motley Fool - Motley Fool - Tue Jun 24, 3:25PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Today it's the Semi-Final stage, and ... (full story)
Vertex Cystic Fibrosis Success Quells Street's Doubts
at Investor's Business Daily - Tue Jun 24, 10:31AM CDT
Biotech Vertex Pharmaceuticals (VRTX) said Tuesday that its cystic-fibrosis regimen hit its goals in a late-stage study, sending shares soaring 42% to a 14-year high in the stock market today. Vertex said patients taking a combination of lumacaftor... (full story)
Early Glance: Biotechnology companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.: (full story)
Global Choroidal Neovascularization (CNV) Market 2014-2018 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Jun 24, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbmxjk/global_choroidal) has announced the addition of the "Global Choroidal Neovascularization (CNV) Market 2014-2018" report to their offering. The current competition in the Global CNV market is strong as the available treatment options and marketed products have been successful in meeting the market requirement, while treating the underlying cause of the disease. The current market drugs include Lucentis, approved for CNV associated with wet AMD; Macugen, approved for CNV associated with wet AMD; and Visudyne, approved for CNV associated with wet AMD, presumed ocular histoplasmosis, and pathologic myopia. Apart from these, Avastin, which is currently used as an off-label drug has gradually captured a major share of the market. In addition, the CNV pipeline seems to be promising with various molecules in the development phase. These products are expected to meet the unmet needs in the market and will provide physicians with a wider choice in treating CNV. The Global CNV market is driven by several factors, of which high patient and physician satisfaction is one of the major drivers. High patient and physician satisfaction has resulted in increased demand for CNV treatment therapies. Further, the report states that one of the major challenges is the high cost of treatment. Many patients do not have the required budget for investing in high cost treatment options. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Affitech A/S - Allergan Inc. - Chengdu Kanghong Biotech Co. Ltd. - Gilead Sciences Inc. - Lpath Inc. - Mat Biopharma SAS - Pfizer Inc. - Promedior Inc. - QLT Inc. - Quark Pharmaceuticals Inc. - Resolvyx Pharmaceuticals Inc. - Sanwa Kagaku Kenkyusho Co. Ltd. - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Product Portfolio of Current CNV Therapies - Clinical Pipeline Portpolio - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/vb..._choroidal (full story)
Biotech M&A: Do We Need a New Driver?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 8:25PM CDT
This week's tweet of the week on Biotech Banter comes from LifeSciGuy, who says: Party like it's 2011. HCV still the dominant M&A driver for sector? Not sure if that's a good thing. Need torch passed to something else. He's of course... (full story)
Cost Controls vs. Curing Citizens: Fallout from the U.K.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Just like the protagonist in " Fortunately, Unfortunately " Gilead Sciences is experiencing a disproportionate amount of highs and lows. Fortunately, the big biotech released great phase 3 data out of Japan for an experimental hepatitis-c combo... (full story)
Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:45PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) fell after the company announced that Sanofi (SNY) will give up its development and commercialization rights to oncology candidate, MM-121. (full story)
Better Stock Today Challenge: Gilead vs. Vanguard Natural Resources
David Williamson and Joel South, The Motley Fool - Motley Fool - Mon Jun 23, 12:55PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Today it's the Quarter-Final stage, and ... (full story)
RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 11:10AM CDT
RegeneRx Biopharmaceuticals, Inc. (RGRX) and Lee's Pharmaceutical announced that the Chinese regulatory authority has accepted a phase II investigational new drug application for RGN-259. (full story)
Cubist Gains FDA Approval for Sivextro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:50AM CDT
Cubist's (CBST) Sivextro gained FDA approval for the ABSSSI indication. (full story)
Novo Nordisk Reveals Positive Data on Victoza 3 mg - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:30AM CDT
Novo Nordisk A/S's (NVO) Victoza 3 mg showed statistically significant results in a phase IIIa study for chronic weight management. (full story)
Overall Average: 64% Buy
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - 2 hrs 7 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading: (full story)
Midday Glance: Biotechnology companies
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.: (full story)
Strength Seen in Vertex Pharmaceuticals Incorporated (VRTX) as Stock Shoots 40.41% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:44AM CDT
Vertex Pharmaceuticals Incorporated (VRTX) was a big mover last session, as the company saw its shares catapult over a whopping 40% on the day. (full story)
'Fast Money' Recap: A Mixed Bag for Housing
at The Street - Wed Jun 25, 4:00AM CDT
The trading panel discussed the stock market's big drop, how low the S&P can go and why bonds aren't selling off. (full story)
Should Dividend Investors Eject AbbVie Stock?
David Williamson, The Motley Fool - Motley Fool - Tue Jun 24, 6:01PM CDT
Dividend aristocrat spin-off AbbVie (NYSE: ABBV) has one of the highest yields in health care, but does that make it one of the sector's top dividend stocks? In this video, Motley Fool Healthcare analyst David Williamson will be grading well... (full story)
Vertex Gets Out of TRAFFIC and TRANSPORTs Shares 40% Higher
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 6:01PM CDT
Sometimes good enough really is good enough. But only if you're treating the right patient population. Vertex Pharmaceuticals seems to be really good at picking them. The biotech gets a passing grade for improving lung function in its clinical... (full story)
Up 40%: Is Vertex's Surge Justified?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 24, 3:32PM CDT
Vertex has been one of the most hit-and-miss investments in the biotech industry over the past five years, but investors who have hung in through thick and thin have been rewarded. Despite a short-lived run as the globe's pre-eminent leader in... (full story)
Better Stock Today Challenge: Gilead vs. Kinder Morgan Partners
David Williamson and Joel South, The Motley Fool - Motley Fool - Tue Jun 24, 3:25PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Today it's the Semi-Final stage, and ... (full story)
Vertex Cystic Fibrosis Success Quells Street's Doubts
at Investor's Business Daily - Tue Jun 24, 10:31AM CDT
Biotech Vertex Pharmaceuticals (VRTX) said Tuesday that its cystic-fibrosis regimen hit its goals in a late-stage study, sending shares soaring 42% to a 14-year high in the stock market today. Vertex said patients taking a combination of lumacaftor... (full story)
Early Glance: Biotechnology companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.: (full story)
Global Choroidal Neovascularization (CNV) Market 2014-2018 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Jun 24, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbmxjk/global_choroidal) has announced the addition of the "Global Choroidal Neovascularization (CNV) Market 2014-2018" report to their offering. The current competition in the Global CNV market is strong as the available treatment options and marketed products have been successful in meeting the market requirement, while treating the underlying cause of the disease. The current market drugs include Lucentis, approved for CNV associated with wet AMD; Macugen, approved for CNV associated with wet AMD; and Visudyne, approved for CNV associated with wet AMD, presumed ocular histoplasmosis, and pathologic myopia. Apart from these, Avastin, which is currently used as an off-label drug has gradually captured a major share of the market. In addition, the CNV pipeline seems to be promising with various molecules in the development phase. These products are expected to meet the unmet needs in the market and will provide physicians with a wider choice in treating CNV. The Global CNV market is driven by several factors, of which high patient and physician satisfaction is one of the major drivers. High patient and physician satisfaction has resulted in increased demand for CNV treatment therapies. Further, the report states that one of the major challenges is the high cost of treatment. Many patients do not have the required budget for investing in high cost treatment options. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Affitech A/S - Allergan Inc. - Chengdu Kanghong Biotech Co. Ltd. - Gilead Sciences Inc. - Lpath Inc. - Mat Biopharma SAS - Pfizer Inc. - Promedior Inc. - QLT Inc. - Quark Pharmaceuticals Inc. - Resolvyx Pharmaceuticals Inc. - Sanwa Kagaku Kenkyusho Co. Ltd. - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Product Portfolio of Current CNV Therapies - Clinical Pipeline Portpolio - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/vb..._choroidal (full story)
Biotech M&A: Do We Need a New Driver?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 8:25PM CDT
This week's tweet of the week on Biotech Banter comes from LifeSciGuy, who says: Party like it's 2011. HCV still the dominant M&A driver for sector? Not sure if that's a good thing. Need torch passed to something else. He's of course... (full story)
Cost Controls vs. Curing Citizens: Fallout from the U.K.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Just like the protagonist in " Fortunately, Unfortunately " Gilead Sciences is experiencing a disproportionate amount of highs and lows. Fortunately, the big biotech released great phase 3 data out of Japan for an experimental hepatitis-c combo... (full story)
Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:45PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) fell after the company announced that Sanofi (SNY) will give up its development and commercialization rights to oncology candidate, MM-121. (full story)
Better Stock Today Challenge: Gilead vs. Vanguard Natural Resources
David Williamson and Joel South, The Motley Fool - Motley Fool - Mon Jun 23, 12:55PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Today it's the Quarter-Final stage, and ... (full story)
RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 11:10AM CDT
RegeneRx Biopharmaceuticals, Inc. (RGRX) and Lee's Pharmaceutical announced that the Chinese regulatory authority has accepted a phase II investigational new drug application for RGN-259. (full story)
Cubist Gains FDA Approval for Sivextro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:50AM CDT
Cubist's (CBST) Sivextro gained FDA approval for the ABSSSI indication. (full story)
Novo Nordisk Reveals Positive Data on Victoza 3 mg - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:30AM CDT
Novo Nordisk A/S's (NVO) Victoza 3 mg showed statistically significant results in a phase IIIa study for chronic weight management. (full story)
